Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9940938 | 0.98 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17062760 | 0.72 | — | — | |
| SCHEMBL2890718 | 0.69 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8578338 | 0.68 | — | — | |
| SCHEMBL9199798 | 0.64 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3PARP1 | |
| SCHEMBL985423 | 0.64 | ALDH1A1 (0.33) | PARP1 | |
| SCHEMBL532873 | 0.63 | NPC1 (0.50) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8358592 | 0.63 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3659273 | 0.63 | ALOX15 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18285512 | 0.63 | SLC6A2 (0.30) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| EP-3356367-A1 | FUSED PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2018-08-08 | — | — | EP | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3022193-B1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2885285-B1 | PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2016-10-19 | — | — | EP | disclosed |
| US-9428464-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9403830-B2 | Inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| EP-2651891-B1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| EP-3022193-A1 | INHIBITORS OF LEUKOTRIENE PRODUCTION | Boehringer Ingelheim International GmbH (DE) | 2016-05-25 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008090117-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090116-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008090115-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2008-07-31 | — | — | WO | disclosed |
| EP-1666465-B1 | Composition comprising a tachykinin receptor antagonist and a selective serotonin reuptake inhibitor | GLAXO GROUP LTD (GB) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008046882-A2 | COMPOSITION COMPRISING AN NK-1 RECEPTOR ANTAGONIST AND AN SSRI FOR THE TREATMENT OF TINNITUS AND HEARING LOSS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-7189713-B2 | Piperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| EP-1666465-A1 | Composition comprising a tachykinin receptor antagonist and a selective serotonin reuptake inhibitor | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| EP-1472256-B1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2005-11-02 | — | — | EP | disclosed |
| US-20050176715-A1 | Piperidine derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | SLC6A2 2323/4885SLC6A4 1317/4885SLC6A3 2277/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | SLC6A2 2323/4885SLC6A4 1317/4885SLC6A3 2277/4885 |
| US-20050176715-A1 | Piperidine derivatives | NPSR1, NPY5R, SSTR5 | SLC6A2 741/4885SLC6A4 309/4885SLC6A3 629/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | SLC6A2 2323/4885SLC6A4 1317/4885SLC6A3 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.